French drugmaker Sanofi (Euronext: SAN) was trading more than 3% higher during Thursday afternoon’s trading in Paris, as the company earlier announced its financial results for the second quarter of 2024, and its latest forecasts for the rest of the year.
Sales for the quarter grew by 7.8% to 10.75 billion euros ($11.7 billion), driven by a 29% rise in sales of the mega blockbuster immunology product Dupixent (dupilumab). Bringing in 3.3 billion euros in a quarter was a new high, and the drug remains on course to generate revenue this year of around 13 billion euros.
'Progress in our pipeline'
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze